Microbiology International

800ezmicro.com

Microbiology International specializes in autoclaves, peristaltic pumps, air samplers, anaerobic chambers, plate pourers, media preparators and stomachers as well as other automation equipment used in microbiological laboratories. We also provide laboratories with the most innovative automation equipment as well as the highest quality rapid detection kits and consumable products for pathogen detection available worldwide. Our equipment quickly automates tedious, manual lab processes and when combined with our ability to provide customized culture media products, we are able to make your lab as efficient as possible.

Related News

INDUSTRIAL IMPACT

ALLOY THERAPEUTICS RAISES $42 MILLION SERIES D FINANCING TO ACCELERATE DISCOVERY TECHNOLOGY DEVELOPMENT ACROSS BIOLOGIC MODALITIES

Alloy Therapeutics, Inc. | October 04, 2022

news image

Alloy Therapeutics, a biotechnology ecosystem company, has closed $42 million in Series D financing led by its existing investors 8VC and Mubadala Capital and joined by return investors Thiel Capital, Presight Capital, Founders Fund, and other unnamed family offices and sovereign wealth funds. Alloy will use proceeds from the Series D financing to further support the drug discovery community with new pre-competitive drug discovery technologies in new biologic modalities and new partnership model...

Read More

MEDICAL

ABC OPENS COMMERCIAL MEL BIOSURFACTANT PRODUCTION IN IRVINE, CA

ABC | May 19, 2022

news image

Advanced BioCatalytics (ABC) is pleased to announce the opening of our new biosurfactant commercial pilot plant in Irvine California. The plant reflects the successful collaboration of the ABC R&D team and Dr. Wenjie Xia, professor of Microbiology at Nankai University in Tianjin China. The commercial pilot plant is the first step in commercial scale up of new glycolipid (biosurfactants) and is the first plant to produce commercial quantities of mannosylerythritol lipids (MEL) in North Americ...

Read More

MEDICAL

ASPECT BIOSYSTEMS ANNOUNCES PARTNERSHIP WITH JDRF TO ADVANCE DEVELOPMENT OF A BIOENGINEERED TISSUE THERAPEUTIC TO TREAT TYPE 1 DIABETES

Aspect Biosystems | April 07, 2022

news image

Aspect Biosystems ("Aspect"), a biotechnology company developing bioengineered tissue therapeutics to transform how we treat disease, is pleased to announce a partnership with JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization. The JDRF-Aspect partnership supports Aspect's focus on developing a bioengineered tissue therapeutic for type 1 diabetes that will provide insulin independence and control of blood sugar without the need for chro...

Read More

INDUSTRIAL IMPACT

GILEAD SCIENCES TO ACQUIRE MIROBIO

Gilead Sciences, Inc. | August 05, 2022

news image

Gilead Sciences, Inc. and MiroBio, a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, today announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in cash, subject to customary adjustments. The acquisition will provide Gilead with MiroBio’s proprietary discovery platform and entire portfolio of imm...

Read More
news image

INDUSTRIAL IMPACT

ALLOY THERAPEUTICS RAISES $42 MILLION SERIES D FINANCING TO ACCELERATE DISCOVERY TECHNOLOGY DEVELOPMENT ACROSS BIOLOGIC MODALITIES

Alloy Therapeutics, Inc. | October 04, 2022

Alloy Therapeutics, a biotechnology ecosystem company, has closed $42 million in Series D financing led by its existing investors 8VC and Mubadala Capital and joined by return investors Thiel Capital, Presight Capital, Founders Fund, and other unnamed family offices and sovereign wealth funds. Alloy will use proceeds from the Series D financing to further support the drug discovery community with new pre-competitive drug discovery technologies in new biologic modalities and new partnership model...

Read More
news image

MEDICAL

ABC OPENS COMMERCIAL MEL BIOSURFACTANT PRODUCTION IN IRVINE, CA

ABC | May 19, 2022

Advanced BioCatalytics (ABC) is pleased to announce the opening of our new biosurfactant commercial pilot plant in Irvine California. The plant reflects the successful collaboration of the ABC R&D team and Dr. Wenjie Xia, professor of Microbiology at Nankai University in Tianjin China. The commercial pilot plant is the first step in commercial scale up of new glycolipid (biosurfactants) and is the first plant to produce commercial quantities of mannosylerythritol lipids (MEL) in North Americ...

Read More
news image

MEDICAL

ASPECT BIOSYSTEMS ANNOUNCES PARTNERSHIP WITH JDRF TO ADVANCE DEVELOPMENT OF A BIOENGINEERED TISSUE THERAPEUTIC TO TREAT TYPE 1 DIABETES

Aspect Biosystems | April 07, 2022

Aspect Biosystems ("Aspect"), a biotechnology company developing bioengineered tissue therapeutics to transform how we treat disease, is pleased to announce a partnership with JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization. The JDRF-Aspect partnership supports Aspect's focus on developing a bioengineered tissue therapeutic for type 1 diabetes that will provide insulin independence and control of blood sugar without the need for chro...

Read More
news image

INDUSTRIAL IMPACT

GILEAD SCIENCES TO ACQUIRE MIROBIO

Gilead Sciences, Inc. | August 05, 2022

Gilead Sciences, Inc. and MiroBio, a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, today announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in cash, subject to customary adjustments. The acquisition will provide Gilead with MiroBio’s proprietary discovery platform and entire portfolio of imm...

Read More